Correlation of docetaxel administration duration, dosage, and patient age with epiphora severity: a retrospective observational study in breast cancer patients

  • Riani Erna 
    Sriwijaya University
    Indonesia
  • Dita Mintardi
    Sriwijaya University
    Indonesia
  • Nur Qodir
    Sriwijaya University
    Indonesia
  • Erial Bahar
    Sriwijaya University
    Indonesia

Abstract

Epiphora, or excessive tearing, is a frequent yet under-recognised adverse effect of docetaxel, a taxane-based chemotherapeutic agent used in breast cancer treatment. Inflammatory and fibrotic changes within the lacrimal drainage system are hypothesised as the primary mechanisms. This study aimed to evaluate the correlation between docetaxel administration duration and epiphora severity, alongside the impact of cumulative dosage and patient age. A retrospective observational study was conducted at Mohammad Hoesin Hospital Palembang, involving 25 breast cancer patients who reported epiphora during docetaxel chemotherapy. Patients with pre-existing ocular conditions, prior lacrimal surgery, or concurrent use of epiphora-inducing medications were excluded. Epiphora severity was assessed using the Munk score, and statistical analyses included Pearson’s correlation and multiple regression. Findings demonstrated a strong positive correlation between epiphora severity and docetaxel duration (r = 0.645, p < 0.05), cumulative dosage (r = 0.618, p < 0.05), and patient age (r = 0.703, p < 0.05). Limitations include the retrospective design, small sample size, and subjective assessment tools. These results emphasise the importance of monitoring for epiphora during docetaxel therapy, with early ophthalmologic intervention recommended. Further prospective studies are needed to clarify pathophysiological mechanisms and optimise management strategies for chemotherapy-induced epiphora.

Lisensing Information
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References
  1. Canino, F., Omarini, C., Cerma, K., Moscetti, L., Tornincasa, A., Trudu, L., Dominici, M., & Piacentini, F. (2022). Ocular toxicity in breast cancer management: manual for the oncologist. Clinical Breast Cancer, 22(4), 289–299.
  2. Crown, J., O’Leary, M., & Ooi, W.-S. (2004). Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. The Oncologist, 9(S2), 24–32.
  3. Dalvin, L. A., Shields, C. L., Orloff, M., Sato, T., & Shields, J. A. (2018). Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects. Retina, 38(6), 1063–1078.
  4. Esmaeli, B., Burnstine, M. A., Ahmadi, M. A., & Prieto, V. G. (2003). Docetaxel-induced histologic changes in the lacrimal sac and the nasal mucosa. Ophthalmic Plastic & Reconstructive Surgery, 19(4), 305–308.
  5. Esmaeli, B., Hidaji, L., Adinin, R. B., Faustina, M., Coats, C., Arbuckle, R., Rivera, E., Valero, V., Tu, S., & Amir Ahmadi, M. (2003). Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer: Interdisciplinary International Journal of the American Cancer Society, 98(3), 504–507.
  6. Figgitt, D. P., & Wiseman, L. R. (2000). Docetaxel: an update of its use in advanced breast cancer. Drugs, 59, 621–651.
  7. Fraunfelder, F. T., Fraunfelder, F. W., & Chambers, W. A. (2014). Drug-Induced Ocular Side effects: clinical ocular toxicology E-Book: clinical ocular toxicology. Elsevier Health Sciences.
  8. Galindo-Ferreiro, A., de Prado Otero, D. S., Marquez, P. I. G., & Schellini, S. (2021). Recurrent and recalcitrant upper lid cicatricial entropion following combined chemotherapy: Clinical and pathology correlation. Saudi Journal of Ophthalmology, 35(4), 347–349.
  9. Grant, W. M., & Schuman, J. S. (1993). Toxicology of the eye: effects on the eyes and visual system from chemicals, drugs, metals and minerals, plants, toxins and venoms; also systemic side effects from eye medications (Vol. 1). Charles C Thomas Publisher.
  10. Gupta, N., & Gupta, N. (2021). Anatomy of Lacrimal Drainage System. Endoscopic Dacryocystorhinostomy, 9–21.
  11. Hernández-Vargas, H., Palacios, J., & Moreno-Bueno, G. (2007). Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis. Oncogene, 26(20), 2902–2913.
  12. Kashkouli, M. B., Zolfaghari, R., Es’ haghi, A., Amirsardari, A., Abtahi, M. B., Karimi, N., Alemzadeh, A., & Aghamirsalim, M. (2016). Tear film, lacrimal drainage system, and eyelid findings in subjects with anophthalmic socket discharge. American Journal of Ophthalmology, 165, 33–38.
  13. Kintzel, P. E., Michaud, L. B., & Lange, M. K. (2006). Docetaxel‐associated epiphora. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 26(6), 853–867.
  14. Lyseng-Williamson, K. A., & Fenton, C. (2005). Docetaxel: a review of its use in metastatic breast cancer. Drugs, 65, 2513–2531.
  15. Ma, J., Pazo, E. E., Zou, Z., & Jin, F. (2020). Prevalence of symptomatic dry eye in breast cancer patients undergoing systemic adjuvant treatment: A cross-sectional study. The Breast, 53, 164–171.
  16. Maganti, N., Pathak, C. A., & Burkat, C. N. (2021). Canalicular Stenosis Secondary to Chemotherapeutic Agents. Advances in Ophthalmology and Optometry, 6, 379–389.
  17. Mann, J., Yang, N., Montpetit, R., Kirschenman, R., Lemieux, H., & Goping, I. S. (2020). BAD sensitizes breast cancer cells to docetaxel with increased mitotic arrest and necroptosis. Scientific Reports, 10(1), 355.
  18. McGwin Jr, G., Contorno, T., Vicinanzo, M. G., & Owsley, C. (2023). The Association Between Taxane Use and Lacrimal Disorders. Current Eye Research, 48(9), 873–877.
  19. Noguchi, S. (2006). Predictive factors for response to docetaxel in human breast cancers. Cancer Science, 97(9), 813–820.
  20. Ogawa, Y., Kawakami, Y., & Tsubota, K. (2021). Cascade of inflammatory, fibrotic processes, and stress-induced senescence in chronic GVHD-related dry eye disease. International Journal of Molecular Sciences, 22(11), 6114.
  21. Pakdel, F., & Kashkouli, M. B. (2009). Lacrimal drainage obstruction associated with topical and systemic medications. Journal of Ophthalmic & Vision Research, 4(4), 270.
  22. Rzeszotarska, A., Stodolska-Nowak, A., Kufel-Grabowska, J., Nowakowski, B., & Kocięcki, J. (2019). Ocular side effects of the taxane-based chemotherapy–do only vascular disorders matter? OncoReview, 9(3 (35)), 59–63.
  23. Schaefer, J. L., & Schaefer, D. P. (2020). Acquired causes of lacrimal system obstructions. In Smith and Nesi’s Ophthalmic Plastic and Reconstructive Surgery (pp. 521–543). Springer.
  24. Schmid, K. E., Kornek, G. V, Scheithauer, W., & Binder, S. (2006). Update on ocular complications of systemic cancer chemotherapy. Survey of Ophthalmology, 51(1), 19–40.
  25. Shalli, K., Brown, I., Heys, S. D., & Schofield, C. A. (2005). Alterations of β‐tubulin isotypes in breast cancer cells resistant to docetaxel. The FASEB Journal, 19(10), 1299–1301.
  26. Sieśkiewicz, A., Łysoń, T., Rogowski, M., Bielecki, M., Gindzienska-Sieskiewicz, E., Olszewska, E., & Bielecki, P. (2021). Assessment of lacrimal duct patency in patients undergoing endoscopic medial maxillectomy. Journal of Clinical Medicine, 10(2), 245.
  27. Smith, I. C., Heys, S. D., Hutcheon, A. W., Miller, I. D., Payne, S., Gilbert, F. J., Ah-See, A. K., Eremin, O., Walker, L. G., & Sarkar, T. K. (2002). Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. Journal of Clinical Oncology, 20(6), 1456–1466.
  28. Sodhi, M., Yeung, S. N., Maberley, D., Mikelberg, F., & Etminan, M. (2022). Risk of ocular adverse events with taxane-based chemotherapy. JAMA Ophthalmology, 140(9), 880–884.
  29. Sohrevardi, S. M., Zangeneh, M., Owliaey, H., & Sheikhpour, E. (2024). The Evaluation of Ocular Toxicity of Chemotherapy Drugs. Iranian Journal of Pediatric Hematology and Oncology, 14(4), 300–309.
  30. Stoicescu, E. A., Burcea, M., Iancu, R. C., Zivari, M., Popa Cherecheanu, A., Bujor, I. A., Rastoaca, C., & Iancu, G. (2021). Docetaxel for breast cancer treatment-side effects on ocular surface, a systematic review. Processes, 9(7), 1086.
  31. Stoicescu, E. A., Iancu, R. C., Cherecheanu, A. P., & Iancu, G. (2023). Ocular adverse effects of anti-cancer chemotherapy. Journal of Medicine and Life, 16(6), 818.
  32. Swampillai, A. J., & McMullan, T. F. (2012). Epiphora. British Journal of Hospital Medicine, 73(Sup11), C162–C165.
  33. van Eijk, M., Vermunt, M. A. C., van Werkhoven, E., Wilthagen, E. A., Huitema, A. D. R., & Beijnen, J. H. (2022). The influence of docetaxel schedule on treatment tolerability and efficacy in patients with metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. BMC Cancer, 22(1), 104.

Downloads

PDF

Statistic

Abstract Views
: 83 times
PDF
: 50 times